Health & Biotech Stock Insiders Podcast: Investors eye Opyl’s strong revenues and expanded offering following launch of ‘Opin’ clinical trial recruitment platform August 19, 2021 Opyl is an ASX-listed company that provides biopharma and health organisations access to emerging AI-assisted technologies and professional guidance. ASX health stocks: CSL leads another round of strong earnings, but FY22 outlook remains subdued August 18, 2021 The ASX 200 health stocks index (XHJ) fell by 0.76% this morning, compared to the broader index which rose by… Wellnex Life secures key licensing deal with Mark Wahlberg-led fitness and nutrition brand, shares leap ahead August 18, 2021 Special Report: The deal confirms the ability of the WNX management team to execute on key partnerships as it builds… TALi gets global recognition for its digital health tech in major deal with US market leader Akili Interactive August 18, 2021 Special Report: The partnership has the potential to deliver $51m in revenues along with annuity-based royalty payments. This ASX-listed healthcare ETF returned 33pc in 2020 – and it’s not Blackrock’s IXJ August 18, 2021 Healthcare is a popular thematic, and Blackrock’s iShares Global Healthcare ETF (ASX:IXJ) is one of the biotech investing crowd's favourite… Check up: Rhinomed (ASX:RNO) soars with NSW COVID contract, and genetic testing fails to impress August 18, 2021 It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and… ASX Health Stocks: Osprey jumps 8% on solid first half; Bard1 concludes successful study August 17, 2021 The ASX 200 health stocks index (XHJ) fell by 0.21% this morning, compared to the broader index which fell by… Australian biotech figurehead Paul Hopper raises $20 million for his latest pre-IPO venture August 17, 2021 Paul Hopper has been behind a number of successful oncology biotechs, and his latest venture is one of the few… Supermarket giant Coles will stock ECS Botanics’ hemp seed oil August 16, 2021 Special Report: ECS Botanics Holdings has secured a deal to stock its Extra Virgin Tasmanian Hemp Seed Oil in Coles… Creso Pharma’s psychedelics subsidiary Halucenex receives Canadian licence approval, targets Phase II trials on PTSD August 16, 2021 Special Report: The new licence won by Halucenex will unlock several opportunities for Creso Pharma in the global psychedelic market,… Next» « Previous